Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Ivan de Kouchkovsky (ucsf)

Description

Summary

This phase II trial studies the use of 68Ga-PSMA-11 positron emission tomography (PET) in diagnosing patients with prostate cancer that continues to grow despite the surgical removal of the testes or medical intervention to block androgen production (castration resistant), and has spread to other places in the body (metastatic). 68Ga- PSMA-11 is a new imaging agent that may help get more detailed pictures of the tumor. This trial aims to see whether using 68Ga-PSMA-11 PET scans may help doctors learn more about where disease is located in the body.

Official Title

A Phase 2 Study of 68Ga-PSMA-11 PET in Patients With Metastatic Castration Resistant Prostate Cancer

Details

Keywords

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Carcinoma, Prostatic Neoplasms, Gallium 68 PSMA-11, 68Ga-PSMA-11, Positron Emission Tomography (PET)

Eligibility

Location

  • University of California San Francisco
    San Francisco California 94143 United States

Lead Scientist at University of California Health

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Thomas Hope
ID
NCT04716725
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 15 people participating
Last Updated